Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Q2

This article was originally published in The Tan Sheet

Executive Summary

Gross margin based on total revenues reached 72.2%, due in large part to completion of the integration of Selsun Blue manufacturing into Chattem's facilities, CEO Zan Guerry says during June 20 analysts call. For second quarter ended May 31, Chattem recorded an 8% increase in total revenues to $63.6 mil. and a 33% jump in net income to $7.5 mil. Guerry maintained the imminent launch of Icy Hot Back Patch, coupled with the introduction of a new topical analgesic in Q1 2004, should substantially boost sales for the firm (1"The Tan Sheet" March 24, 2003, In Brief). Q2 topical analgesic sales were down year-over-year, Guerry noted, due to success of competitor P&G's ThermaCare heat wraps...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel